The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
about
Neonatal Vaccination: Challenges and Intervention StrategiesInactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses.Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal ResponsesEfficient generation of monoclonal antibodies against peptide in the context of MHCII using magnetic enrichment.Pilin Vaccination Stimulates Weak Antibody Responses and Provides No Protection in a C57Bl/6 Murine Model of Acute Clostridium difficile InfectionAlternative administration routes and delivery technologies for polio vaccines.The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4(+) T cells following parenteral immunization.Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles.Preformulation studies with the Escherichia coli double mutant heat-labile toxin adjuvant for use in an oral vaccine.Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection.Structural Characterization and Physicochemical Stability Profile of a Double Mutant Heat Labile Toxin Protein Based Adjuvant.Vaccine adjuvants: smart components to boost the immune system.Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice.Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLTRotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model
P2860
Q28066069-7CBA14EC-DF0D-4187-B6DE-16BACD355B66Q36616041-6DF2774D-0B05-47CE-9EFD-D0E36080DDF1Q36973944-D667013C-95D7-46B9-BBFC-11A788C8325CQ37010087-74476204-F87B-4D72-BD2C-01789E6648AEQ37052336-0BCC7C55-0D87-4651-BD0F-3BB292F8489BQ38748979-6CCAD352-B95F-4A1D-804A-F6A62CCD4A98Q38796753-3E7D9F4C-AA61-4668-B59E-682325B56919Q39174792-616E2D0F-3465-4B64-A193-F0C23FD0F52FQ40100679-25321853-9B2D-4FDF-8AE5-3C72955F2FD1Q40694023-06EDF83E-47A2-40E7-BDA9-0281257403B1Q47093864-726986DE-1EDA-4065-B930-41C03889F864Q47120596-E6A905B5-A90F-451C-A0CD-B5F0B0544BF5Q47305690-73221FFE-7DA0-4C58-B034-F8CC3D701C24Q50063256-E1CDD081-6E61-47AC-AC0B-5ED8C706A06FQ52725104-6A789D67-69EF-48F1-8FC7-2C782FE7D541Q54230568-FD4E28CB-12A0-4ECF-AA61-A1FCF34AAF27Q55114845-29030FA3-0C41-4709-B9F0-8A0627540319Q57945015-1B14589C-06A7-4761-80AB-4B4DB69F3A41Q58759991-BCFC31F1-14A1-43F3-A37A-F5B135C6BBA0
P2860
The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The novel adjuvant dmLT promot ...... lio vaccine in a murine model.
@en
The novel adjuvant dmLT promot ...... lio vaccine in a murine model.
@nl
type
label
The novel adjuvant dmLT promot ...... lio vaccine in a murine model.
@en
The novel adjuvant dmLT promot ...... lio vaccine in a murine model.
@nl
prefLabel
The novel adjuvant dmLT promot ...... lio vaccine in a murine model.
@en
The novel adjuvant dmLT promot ...... lio vaccine in a murine model.
@nl
P2093
P1433
P1476
The novel adjuvant dmLT promot ...... lio vaccine in a murine model.
@en
P2093
David L Bauer
Elizabeth B Norton
John D Clements
Louise B Lawson
M Steven Oberste
P304
P356
10.1016/J.VACCINE.2015.02.069
P407
P577
2015-03-09T00:00:00Z